Please login to the form below

Not currently logged in
Email:
Password:

Oxford BioDynamics

This page shows the latest Oxford BioDynamics news and features for those working in and with pharma, biotech and healthcare.

Latest appointments

  • Paul Stockdale joins Oxford BioDynamics as CFO Paul Stockdale joins Oxford BioDynamics as CFO

    Paul Stockdale joins Oxford BioDynamics as CFO. He takes over from Katie Long at the UK biotech. ... A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome

  • Martin Reeves joins Oxford BioDynamics Martin Reeves joins Oxford BioDynamics

    Martin Reeves joins Oxford BioDynamics. He takes up a senior vice president role. ... Oxford BioDynamics – a spin out company from the University of Oxford – has appointed Martin Reeves as its new senior vice president, commercial development.

  • Caldan Therapeutics bolsters senior team Caldan Therapeutics bolsters senior team

    Dr Boyd currently serves as chief financial officer at private life sciences companies Oxford BioDynamics and Enterprise Therapeutics, and was interim-chief financial officer for Tiziana Pharmaceuticals between 2014 and 2015.

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...

Infographics